米拉贝隆联合索利那新对比单药及安慰剂治疗膀胱过度活动症的疗效与安全性(SYNERGY研究)
SYNERGY研究纳入伴尿失禁的膀胱过度活动症患者,随机接受索利那新5 mg联合米拉贝隆25或50 mg、各单药或安慰剂治疗12周。联合治疗在多数疗效指标上优于相应单药,效应量大致符合叠加效应,但索利那新5 mg联合米拉贝隆50 mg在尿失禁发作次数这一共同主要终点上未达统计学显著优于米拉贝隆50 mg(P=0.052)。联合治疗组治疗中出现的不良事件略增加,多为轻中度。
要点
- 索利那新5 mg联合米拉贝隆25或50 mg在多数疗效指标上优于相应单药,效应量大致符合叠加效应。
- 索利那新5 mg联合米拉贝隆50 mg对比米拉贝隆50 mg的尿失禁发作次数变化未达统计学显著(P=0.052)。
- 联合治疗组治疗中出现的不良事件略多于单药和安慰剂组,多为轻中度。
核心结论
- 在迄今规模最大的膀胱过度活动症研究中,索利那新5 mg联合米拉贝隆25 mg及索利那新5 mg联合米拉贝隆50 mg在大多数结局指标上对比相应单药提供一致的疗效改善,效应量大致符合叠加效应。
- 索利那新5 mg联合米拉贝隆50 mg在共同主要终点之一(24小时平均尿失禁发作次数自基线变化)对比米拉贝隆50 mg未达统计学显著,但接近统计学显著(P=0.052),另一共同主要终点(24小时排尿次数)的名义P值<0.05。
- 联合治疗对比单药的大多数效应在治疗第4周即可观察到,应答分析中联合治疗对比单药的改善支持若干客观膀胱过度活动症结局指标的临床相关性。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照研究,纳入年龄≥18岁、伴尿失禁的膀胱过度活动症(湿性OAB)患者,症状持续≥3个月,7天排尿日记平均≥8次排尿/24小时、≥1次尿急发作/24小时、≥3次尿失禁发作。
- 经过4周安慰剂导入期后,按2:2:1:1:1:1比例随机分配至索利那新5 mg联合米拉贝隆25 mg组、索利那新5 mg联合米拉贝隆50 mg组、索利那新5 mg组、米拉贝隆25 mg组、米拉贝隆50 mg组或安慰剂组,治疗12周,随后2周单盲安慰剂停药期。
主要发现
- 共同主要疗效指标为24小时平均尿失禁发作次数和24小时排尿次数自基线至治疗结束的变化。
- 索利那新5 mg联合米拉贝隆50 mg对比索利那新5 mg的尿失禁发作次数校正差异为-0.20(标准误0.12)次/24小时(95%CI -0.44, 0.04,P=0.033),对比米拉贝隆50 mg的差异为-0.23(0.12)次/24小时(P=0.052)。
- 次要分析中,联合治疗组对比安慰剂的尿失禁发作次数效应量(索利那新5 mg联合米拉贝隆25 mg组:-0.70次/24小时;索利那新5 mg联合米拉贝隆50 mg组:-0.65次/24小时)高于单药治疗(范围从米拉贝隆25 mg的-0.37次/24小时至索利那新5 mg的-0.45次/24小时)。
- 24小时排尿次数自基线至治疗结束的校正变化,联合治疗组优于单药治疗(索利那新5 mg联合米拉贝隆50 mg组对比索利那新5 mg和米拉贝隆50 mg的名义P值分别为0.006和<0.001;索利那新5 mg联合米拉贝隆25 mg组对比索利那新5 mg和米拉贝隆25 mg的名义P值分别为0.040和0.001)。
- 所有活动治疗组对比安慰剂的24小时排尿次数效应量:索利那新5 mg联合米拉贝隆25 mg组-0.85次/24小时,索利那新5 mg联合米拉贝隆50 mg组-0.95次/24小时,米拉贝隆25 mg组-0.36次/24小时,米拉贝隆50 mg组-0.39次/24小时,索利那新5 mg组-0.56次/24小时。
关键数值与推荐
- 索利那新5 mg联合米拉贝隆50 mg在治疗结束时对急迫性尿失禁发作、尿急发作和夜尿的改善在统计学上显著优于两种单药,效应量似为叠加效应。
- 索利那新5 mg联合米拉贝隆25 mg在除夜尿外的相同变量上统计学显著优于米拉贝隆25 mg。
- 治疗结束时应答分析显示,两种联合治疗对比单药在零尿失禁发作患者比例和排尿频率正常化(<8次/24小时)患者比例上的比值比支持联合治疗。
- 联合治疗组对比单药和安慰剂,治疗中出现的不良事件频率略增加,大多数为轻中度。
- 提示尿潴留的事件在联合治疗组对比单药和安慰剂报告略多;残余尿量在联合治疗组对比索利那新5 mg、米拉贝隆单药和安慰剂组略增加;口干、便秘和消化不良在联合治疗组对比单药频率略高;心电图和实验室数据未见担忧。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the potential of solifenacin 5 mg combined with mirabegron 25 or 50 mg to deliver superior efficacy compared with monotherapy, with acceptable tolerability, in the general overactive bladder (OAB) population with urinary incontinence (UI). PATIENTS AND METHODS: After a 4-week placebo run-in, patients aged ≥18 years with wet OAB (urgency, urinary frequency and UI) for ≥3 months who recorded on average ≥8 micturitions/24 h, ≥1 urgency episode/24 h, and ≥3 UI episodes over the 7-day micturition diary, were eligible for randomisation to double-blind treatment [2:2:1:1:1:1 ratio, solifenacin 5 mg + mirabegron 25 mg (combined S5 + M25 group); solifenacin 5 mg + mirabegron 50 mg (combined S5 + M50 group); solifenacin 5 mg; mirabegron 25 mg; mirabegron 50 mg; or placebo for 12 weeks], and 2-weeks' single-blind, placebo run-out. Co-primary efficacy variables were change from baseline to end of treatment (EoT) in the mean number of UI episodes/24 h and micturitions/24 h, assessed using a 7-day electronic micturition diary. Secondary efficacy variables included change from baseline to EoT in the mean volume voided/micturition, change from baseline at weeks 4, 8, 12 and EoT in mean number of UI episodes/24 h, micturitions/24 h, urgency episodes/24 h, urgency UI (UUI) episodes/24 h and nocturia episodes/24 h; the percentage of patients (responders) achieving zero UI episodes/24 h at EoT in the last 7 days prior to each visit, micturition frequency normalisation (<8 episodes/24 h) at weeks 4, 8, 12 and EoT; and the number of UUI episodes and nocturia episodes in the 7-day diary. Safety assessments included incidence and frequency of treatment-emergent adverse events (TEAEs), post-void residual (PVR) urine volume, and changes from baseline in laboratory parameters. RESULTS: Whilst the combined S5 + M50 group was superior to solifenacin 5 mg for UI, with a mean (standard error) adjusted difference of -0.20 (0.12) UI episodes/24 h (95% confidence interval -0.44, 0.04, P = 0.033), there was no statistical superiority vs mirabegron 50 mg [-0.23 (0.12) UI episodes/24 h; P = 0.052]. In secondary analyses, all active treatment groups had greater improvements in UI episodes/24 h vs placebo, with effect sizes for the combined therapy groups (combined S5 + M25 group: -0.70 episodes/24 h; combined S5 + M50 group: -0.65 episodes/24 h) that were substantially higher than those obtained with monotherapy (range -0.37 episodes/24 h for mirabegron 25 mg to -0.45 episodes/24 h for solifenacin 5 mg). For micturitions/24 h, adjusted change from baseline to EoT was greater in the combined therapy groups vs monotherapies (combined S5 + M50 group, nominal P values 0.006 and <0.001 vs solifenacin 5 mg and mirabegron 50 mg, respectively; combined S5 + M25 group, nominal P values 0.040 and 0.001 vs solifenacin 5 mg and mirabegron 25 mg, respectively). All active treatment groups had greater improvements in the mean numbers of micturitions/24 h vs placebo, with effect sizes for the combined therapy groups (combined S5 + M25 group: -0.85 micturitions/24 h; combined S5 + M50 group: -0.95 micturitions/24 h) higher than with mirabegron monotherapy (25 mg: -0.36; 50 mg: -0.39 micturitions/24 h) and solifenacin 5 mg (-0.56 micturitions/24 h). The combined S5 + M50 group was statistically significantly superior to both monotherapies at EoT for UUI episodes, urgency episodes and nocturia, with effect sizes that appeared to be additive. The combined S5 + M25 group was statistically significantly superior to mirabegron 25 mg for the same variables, except for nocturia. In responder analyses at the EoT, odds ratios in favour of both combined therapies vs monotherapies were shown for the proportion of patients with zero UI episodes and those achieving micturition frequency normalisation. There was a slightly increased frequency of TEAEs in the combined therapy groups vs monotherapies and placebo. Most of the TEAEs were mild or moderate in severity. Events indicative of urinary retention were reported slightly more frequently in the combined therapy groups vs monotherapy and placebo. PVR volume was slightly increased in the combined therapy groups vs solifenacin 5 mg, mirabegron monotherapy, and placebo groups. There were slightly higher frequencies of dry mouth, constipation, and dyspepsia in the combined therapy groups vs monotherapies. There were no concerns regarding electrocardiograms and laboratory data. CONCLUSION: In the largest OAB study to date, combined therapy with solifenacin 5 mg + mirabegron 25 mg and solifenacin 5 mg + mirabegron 50 mg provided consistent improvements in efficacy compared with the respective monotherapies across most of the outcome parameters, with effect sizes generally consistent with an additive effect. Although the combined S5 + M50 group did not achieve a statistically significant effect vs mirabegron 50 mg in the primary analysis of one of the co-primary endpoints (change from baseline in mean number of UI episodes/24 h), it approached statistical significance (P = 0.052), and the nominal P values for the other co-primary endpoint (micturitions/24 h) were <0.05. Most effects of combined therapy vs monotherapy were observable by week 4. The clinical relevance of the improvements seen with combined therapy for several objective OAB outcome measures was also supported by the improvements of combined therapy vs monotherapy in the responder analyses.
引用
- Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017. PMID: 28418102. doi:10.1111/bju.13882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。